CSIMarket Company Name, Ticker, Suppliers, else..
 
Kazia Therapeutics Limited  (NASDAQ: KZIA)
Other Ticker:  
 
 
Price: $1.7000 $0.23 15.646%
Day's High: $1.73 Week Perf: 20.14 %
Day's Low: $ 1.44 30 Day Perf: -43.71 %
Volume (M): 117 52 Wk High: $ 15.80
Volume (M$): $ 199 52 Wk Avg: $3.50
Open: $1.44 52 Wk Low: $1.32



 Market Capitalization (Millions $) 45
 Shares Outstanding (Millions) 26
 Employees 17
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Kazia Therapeutics Limited
Kazia Therapeutics Limited is a global biotechnology company that specializes in the development of innovative cancer therapies. Founded in 2015, the company focuses on discovering and commercializing novel drugs to target difficult-to-treat cancers. Kazia Therapeutics is known for its lead drug candidate, paxalisib (formerly GDC-0084), which is being developed as a potential treatment for glioblastoma, a highly aggressive form of brain cancer. The company works closely with leading research institutions and healthcare providers to advance its pipeline of drug candidates and improve patient outcomes. Kazia Therapeutics is headquartered in Sydney, Australia, with operations and collaborations spanning across the United States and Europe.


   Company Address: Three International Towers, Level 24, 300 Barangaroo Avenue Sydney 2000
   Company Phone Number: 9472-4101   Stock Exchange / Ticker: NASDAQ KZIA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GTHX        0.28% 
KPTI        0.28% 
NRIX        0.28% 
RYTM        0.28% 
SUPN        0.28% 
YMAB        0.28% 
• View Complete Report
   



Kazia Therapeutics Limited

Kazia Therapeutics Limited Faces Challenges Amidst Fourth Quarter of 2023 Earnings

Kazia Therapeutics Limited, a biotechnology company specializing in the development of innovative cancer therapies, recently reported its financial results for the fourth quarter of the 2023 earnings season. While the company experienced a loss of $-0.11 per share compared to $-0.19 in the previous year, it is important to note that this deficit per share has decreased by -96% from $0.03 million in the same period a year prior.
In terms of revenue, Kazia Therapeutics Limited saw a sharp decrease to $0.00 million from $0.03 million in the previous year. This decline in revenue is in contrast to the overall Major Pharmaceutical Preparations sector, which posted a revenue rise during the same period. It is evident that Kazia Therapeutics Limited faces challenges in generating significant revenue, and this downturn in top-line performance is a cause for concern.






Kazia Therapeutics Limited's Segments
Licensing revenue    92.74 % of total Revenue
Licensing revenue Timing of revenue recognition    92.74 % of total Revenue
Sale of paxalisib    0.28 % of total Revenue
Sale of paxalisib Timing of revenue recognition    0.28 % of total Revenue
KR    93.03 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com